I am a nuclear medicine physician and Director of the Targeted Radiotherapy Section in the Department of Radiology. My area of expertise is targeted radionuclide therapy, PET, and molecular imaging. I have a particular interest in developing new targeted therapeutic agents.
Prior to joining Memorial Sloan Kettering Cancer Center, I was a tenured investigator at the National Institutes of Health. The collaborative work I did there in Phase 1 and Phase 2 clinical trials has contributed to advancements in the field of radioimmunotherapy.
- Clinical Expertise: General Nuclear Medicine; Radiolabeled Antibodies for Tumor Imaging and Therapy; Radionuclide Therapy; Positron Emission Tomography
- Languages Spoken: English
- Education: MD, University of Puerto Rico
- Residencies: University District Hospital (San Juan, Puerto Rico); University of Washgington (Seattle)
- Board Certifications: Internal Medicine; Nuclear Medicine
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Jorge A. Carrasquillo
Clinical Trials Co-Investigated by Jorge A. Carrasquillo
- A Phase I Study of Intraperitoneal Radioimmunotherapy with 131I-8H9 for Patients with Desmoplastic Small Round Cell Tumors and Other Solid Peritoneal Tumors
- A Pilot Phase II Study of Targeted Radiotherapy with 131I-MIBG and Arsenic Trioxide in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
- A Study of Imaging to Detect HER2 Positive Cancer Cells in Women with Breast Cancer, to Guide the Use of HER2 Targeted Therapies